IMMUNOTECH BIOPHARM LTD |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.39 HKD | +6.94% |
|
+11.88% | -32.20% |
| 21/06 | Immunotech Biopharm Unit Sells 80 Million Yuan of Certificates of Deposit | MT |
| 29/03 | Immunotech Biopharm Posts Nearly 335 Million Yuan Loss in 2023 | MT |
Valuation
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|
| Capitalization 1 | 4,833 | 7,061 | 2,104 | 2,339 |
| Enterprise Value (EV) 1 | 4,039 | 6,819 | 2,175 | 2,619 |
| P/E ratio | -9.49 x | -19.9 x | -6.6 x | -6.98 x |
| Yield | - | - | - | - |
| Capitalization / Revenue | - | - | - | - |
| EV / Revenue | - | - | - | - |
| EV / EBITDA | -12.1 x | -21 x | -9.41 x | -14.6 x |
| EV / FCF | -4,15,71,620 x | -3,38,48,331 x | -1,48,59,534 x | -2,16,79,092 x |
| FCF Yield | -0% | -0% | -0% | -0% |
| Price to Book | 4.29 x | 8.59 x | 4.14 x | 13.5 x |
| Nbr of stocks (in thousands) | 5,14,584 | 5,14,584 | 5,14,584 | 5,14,584 |
| Reference price 2 | 9.393 | 13.72 | 4.089 | 4.545 |
| Announcement Date | 20/04/21 | 25/04/23 | 25/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net sales | - | - | - | - | - | - |
| EBITDA 1 | -42.32 | -92.1 | -334 | -324.3 | -231.1 | -178.8 |
| EBIT 1 | -44.3 | -97.73 | -347.7 | -345.2 | -274.2 | -231 |
| Operating Margin | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -34.89 | -109.1 | -439.1 | -354.6 | -321.1 | -335.5 |
| Net income 1 | -34.77 | -108.8 | -439 | -354.2 | -318.1 | -334.8 |
| Net margin | - | - | - | - | - | - |
| EPS 2 | -0.1061 | -0.2900 | -0.9900 | -0.6900 | -0.6200 | -0.6507 |
| Free Cash Flow | - | -65.45 | -97.16 | -201.4 | -146.3 | -120.8 |
| FCF margin | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - |
| Announcement Date | 29/06/20 | 29/06/20 | 20/04/21 | 25/04/23 | 25/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 70.3 | 280 |
| Net Cash position 1 | 140 | 243 | 794 | 242 | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | -0.3044 x | -1.567 x |
| Free Cash Flow | - | -65.5 | -97.2 | -201 | -146 | -121 |
| ROE (net income / shareholders' equity) | - | -39% | -59.7% | -36.3% | -48.3% | -99.1% |
| ROA (Net income/ Total Assets) | - | -17.5% | -26.7% | -18.7% | -17.3% | -16.7% |
| Assets 1 | - | 620 | 1,644 | 1,895 | 1,835 | 2,001 |
| Book Value Per Share 2 | 0.6600 | 0.4400 | 2.190 | 1.600 | 0.9900 | 0.3400 |
| Cash Flow per Share 2 | 0.3900 | 0.7400 | 1.640 | 0.6900 | 0.1100 | 0.1000 |
| Capex 1 | 35.1 | 13.8 | 25 | 146 | 68.2 | 19.6 |
| Capex / Sales | - | - | - | - | - | - |
| Announcement Date | 29/06/20 | 29/06/20 | 20/04/21 | 25/04/23 | 25/04/23 | 29/04/24 |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -32.20% | 209M | |
| +16.44% | 122B | |
| +18.94% | 113B | |
| +18.81% | 26.22B | |
| -25.37% | 19.01B | |
| -19.77% | 15.71B | |
| -20.20% | 15.22B | |
| -47.37% | 14.72B | |
| +59.91% | 14.58B | |
| +4.35% | 13.84B |
- Stock Market
- Equities
- 6978 Stock
- Financials Immunotech Biopharm Ltd
